Yes, glyburide crosses the placenta. For years, it was believed that glyburide had minimal placental transfer, but more recent studies have overturned that assumption. Fetal blood concentrations reach roughly 62% to 70% of maternal levels, meaning a significant amount of the drug makes it into fetal circulation.
How Much Reaches the Fetus
Multiple studies measuring glyburide in umbilical cord blood at delivery have found a consistent pattern: fetal concentrations average about 70% of what’s circulating in the mother’s blood. One study published in PLOS One calculated a fetal-to-maternal ratio of 62%, with a confidence interval stretching from 50% to 74%. This ratio holds relatively steady regardless of how much time has passed since the last dose, suggesting that fetal drug levels closely track maternal levels throughout treatment.
For comparison, metformin (the other oral medication sometimes used for gestational diabetes) crosses the placenta even more freely, reaching 50% to 100% of maternal concentrations. Insulin, on the other hand, does not cross the placenta in meaningful amounts, which is one reason professional guidelines favor it.
Why Transfer Was Originally Thought to Be Low
Early research suggested glyburide barely crossed the placenta at all. There were good theoretical reasons to expect this. Glyburide binds extremely tightly to a protein in the blood called albumin, with 99.8% of the drug attached to protein at any given time. Only the tiny unbound fraction can cross cell membranes, so researchers assumed very little would make it through.
The placenta also has built-in pumps that actively push glyburide back toward the mother. Three different transporter proteins contribute to this effort. The most active one handles about 43% of the efflux, a second contributes around 25%, and a third handles roughly 9%. These pumps work continuously to move glyburide from the fetal side back to the maternal circulation.
Despite all of this, enough glyburide still gets through. One reason is that pregnancy itself lowers albumin levels significantly, from an average of 43 mg/mL in non-pregnant women to about 29 mg/mL during pregnancy. With less albumin available, a larger fraction of glyburide circulates unbound and free to cross into fetal blood. Lab studies confirmed that unbound glyburide transfers at about 73% the rate of a freely diffusing reference compound, meaning it moves across the placenta quite efficiently once it’s not attached to protein.
How Pregnancy Changes Glyburide Metabolism
Pregnancy roughly doubles the rate at which the body clears glyburide. The liver breaks down the drug about 130% faster in pregnant women compared to non-pregnant women, driven by increased activity of the enzymes responsible for processing it. This faster clearance means that a given dose produces lower peak blood levels in a pregnant woman than it would otherwise, and it also means some women need higher or more frequent doses to maintain blood sugar control.
The half-life of glyburide (around six hours) doesn’t change significantly during pregnancy. What changes is how quickly the liver processes each dose, which effectively reduces how much drug is circulating at any point in time. This faster turnover partially offsets the placental transfer, but it doesn’t eliminate fetal exposure.
Risks Linked to Fetal Exposure
The most well-documented concern is neonatal hypoglycemia, or low blood sugar in the newborn. Because glyburide works by stimulating the pancreas to release more insulin, the drug can have the same effect on the fetal pancreas. A meta-analysis published in BMC Endocrine Disorders found that neonatal hypoglycemia was about 5 percentage points more common in babies born to mothers taking glyburide compared to those treated with insulin. The rate of macrosomia (larger-than-normal birth weight) trended higher with glyburide as well, though the difference did not reach statistical significance.
Longer-term follow-up data is limited but worth noting. A study tracking children to ages 5 through 10 found no differences in body weight, body fat, blood pressure, or obesity rates between kids who were exposed to glyburide in the womb and those whose mothers used insulin. However, the glyburide-exposed group scored lower on a test of visual-spatial working memory. No differences appeared on tests of impulse control. The study was small (51 children total), so these findings are preliminary, but they raise questions about subtle neurodevelopmental effects.
Where Guidelines Stand Now
Both ACOG (the American College of Obstetricians and Gynecologists) and the ADA (American Diabetes Association) recommend insulin as the first-line medication for gestational diabetes when diet and exercise aren’t enough. This position was established in 2018 and reaffirmed in the 2024 ADA Standards of Care. The shift away from glyburide as a go-to option was driven in part by the growing evidence of placental transfer and the slightly higher rates of neonatal complications.
Glyburide remains an accepted alternative when insulin isn’t feasible, whether because of cost, access, needle phobia, or other practical barriers. It is the only sulfonylurea drug studied in a large randomized trial for gestational diabetes, and it does effectively lower maternal blood sugar. The trade-off is that a meaningful amount of the drug reaches the fetus, with a small but real increase in the risk of newborn low blood sugar compared to insulin therapy.